In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.
The CALM registry phase 4 study collected data from 267 eyes that were implanted with Yutiq (0.18 mg fluocinolone acetonide intravitreal implant, Alimera Sciences). The most notable finding was the significant reduction of the rate of uveitis recurrence, according to Abbey.
“We can see from this real-world data using Yutiq that the Yutiq implant provides a long-term reduction in